What China’s Zero-COVID Drama Foreshadows
The public’s rejection of the Chinese government's COVID rules raises the political stakes of the next controversial policy.
China Needs Reality-based Governance
The Chinese government can still make policies that meet their citizens' expectations — but it will need to change course fast.
Is the Benefit of China’s Zero-COVID Policy Worth the Cost?
The Chinese strategy may be more economically sound than many assume, but it is time for the country to adopt a less severe approach.
BGI Shakes Up Sequencing
BGI has entered the American genome sequencing market for the first time, forcing scientific innovation to clash with national security.
iHealth’s Omicron Boon
After securing contracts with the U.S. government, the Tianjin-based company's shares have surged 980 percent on the Shenzhen Stock Exchange.
China’s mRNA Boost
With a mRNA vaccine finally in trials, will China change its Covid approach?
Jasper Becker on How to Deal With China Post-Covid
The journalist talks about his new Wuhan book, the "quite damaging" circumstantial evidence and demanding reciprocity with China.
Books for the ‘Red New Deal’
The most essential China books from the last two months that add much-needed depth to the headlines.
Biotech’s Borders
Ever since being named a strategic priority in 2015, China’s biotech industry has shown remarkable progress. But in order to achieve their global ambitions, Chinese...
Yanzhong Huang on Why China’s Strength Is Also Its Weakness
The global health expert talks about China's handling of Covid-19, vaccines, and why — when it comes to policy implementation — China is remarkably resilient...
Shots in the Dark
Leaders all across the world have expressed gratitude for China’s ‘vaccine diplomacy’ — especially as the U.S. has been far less forthcoming with its vaccines....
Opioid Whack-a-Mole
With the arrival of “iso,” Chinese drug manufacturers have found a new way to tap into America’s huge demand for opioids.